| |
Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up - STARTMRK
|
| |
| |
Reported by Jules Levin
CROI 2010
E. DeJesus1, C. Cohen2, J. Lennox3, A. Lazzarin4, D. Berger5, B. Jin6, H. Teppler6, B-Y. Nguyen6, R. Leavitt6, P. Sklar6 for the STARTMRK (P021) Investigators
1Orlando Immunology Center, Orlando, FL, USA; 2Community Research Initiative of New England, Boston, MA, USA; 3Emory University, Atlanta, GA, USA; 4University Vita-Salute San Raffaele, Milan, Italy; 5Northstar Medical Center, University of Illinois at Chicago, Chicago, IL, USA; 6Merck Research Labs, North Wales, PA, USA
|
|
| |
| |
|
|
|
